anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Injectable extracellular matrix (iECM) is a versatile biological material with beneficial properties such as good degradability, promotion of cell survival, immunomodulation, and facilitation of vascular formation. However, intravenous injection of iECM faces challenges like a short retention time in vivo and low concentration at the lesion site. To address these issues, we prepared a composite hydrogel composed of sodium alginate and iECM and administered it via intrapericardial injection, forming a structure akin to cardiac patches within the pericardium. Compared with intramyocardial injection, intrapericardial injection avoids direct myocardial injury and ectopic tumor formation, offering less invasiveness and better biocompatibility. This study demonstrates that the sodium alginate/infusible extracellular matrix (SA/iECM) composite hydrogel can effectively prolong the local retention time of iECM in the heart, enhance electrical conduction between cardiomyocytes, promote angiogenesis at ischemic myocardial sites, inhibit apoptosis in the infarcted region, mitigate left ventricular remodeling postmyocardial infarction (MI), and improve cardiac function after infarction. Precise coordination of cardiomyocyte contraction and relaxation depends on the rhythmic occurrence of calcium-dependent action potentials. Cardiac dysfunction is partially attributed to the disruption of the excitation-contraction coupling (ECC) mechanism, which is associated with prolonged intracellular Ca2+ transients and alterations in contraction and relaxation Ca2+ levels. Our results show that the SA/iECM composite hydrogel improves electrical conduction, as evidenced by increased Cx43 expression and enhanced intercellular electrical connectivity. This research establishes that intrapericardial injection of a SA/iECM composite hydrogel is a safe and effective treatment modality, providing a theoretical basis for the use of biomaterials in MI therapy.
Aberrant activation of the NLRP3 inflammasome is recognized to induce a chronic inflammatory response in the liver, ultimately leading to hepatic fibrosis. HSP90 is suggested to regulate NLRP3 activation and its downstream signaling. This study is the first to explore the potential therapeutic role of pimitespib in mitigating liver fibrosis in rats. The results of the study revealed that pimitespib effectively suppressed hepatic inflammation and fibrogenesis by modulating HSP90's control over the NFκB/NLRP3/caspase-1 axis. In vitro experiments demonstrated that pimitespib reduced LDH levels and increased hepatocyte survival, whereas in vivo, it prolonged the survival of rats with hepatic fibrosis. Additionally, pimitespib exhibited improvements in the function and microscopic characteristics of rat livers. Pimitespib effectively inhibited NFκB, which serves as the priming signal for NLRP3 activation. Pimitespib's inhibitory effect on NLRP3, identified as an HSP90 client protein, plays a central role in the observed anti-fibrotic effect. The simultaneous inhibition of both priming and activation signals of NLRP3 by pimitespib led to a reduction in caspase-1 activity and subsequent suppression of the N-terminal fragment of gasdermin D, ultimately constraining hepatocyte pyroptotic cell death. These diverse effects were associated with a decrease in the transcription of inflammatory mediators IL-1β, IL-18, and TNF-α, as well as the fibrogenic mediators TGF-β, TIMP-1, PDGF-BB, and Col1a1. Moreover, pimitespib induced the expression of HSP70, which could further contribute to the repression of fibrosis development. In summary, our findings provide an evolutionary perspective on managing liver fibrosis, positioning pimitespib as a promising candidate for anti-inflammatory and antifibrotic therapy.
A system is provided for interactively assisting a patient. The system includes a speech synthesizer and recognition unit coupled to a programmed computer. The computer can keep track of a medication and diagnostic testing schedule. The system also includes diagnostic testing equipment coupled to the computer along with medication dispensing equipment. In accordance with a predetermined schedule, the system verbally communicates with the patient, prompts the patient through the various steps necessary to carry out the diagnostic testing and further prompts patient at appropriate times for taking medication. The medication is also provided in combination with the verbal prompts. The system also provides access to a telecommunications link in response to verbal requests of the patient and in one embodiment can move in a limited area adjacent the patient.
Participants randomized to group 1 will receive a 0.5 mg/kg loading dose of racemic ketamine hydrochloride immediately before induction of anesthesia, followed by a continuous 10 mcg/kg/min infusion throughout maintenance of anesthesia, until procedure end (last suture inserted), up to a maximum cumulative dose of 200 mg. Participants will recieve EEG monitoring with the NeuroSENSE monitor.
The patients are given the mushroom extract (Andosan) in doses 30 mlx2 per day for 1 days. The experimental group is selected by randomisation.
Foodstuffs for human or animal consumption are preserved by treating these foodstuffs with a synergistic antibiotic composition comprising (a) an antibiotic being streptomycin, dihydrostreptomycin, chlorotetracycline, chloramphenicol, oxytetracycline, tetracycline, neomycin, erythromycin, carbomycin or viomycin and (b) a synergistically amount of an N6 substituted adenine derivative having one of the following tautomeric formulae <FORM:0978295/A1-A3/1> wherein R represents a hydrocarbyl group and the symbols R1 and R11 each individually represent a hydrogen atom or a hydrocarbyl group which may be substituted with one or more hydroxyl groups or the symbol R1 may represent a hydroxyl or amino group; or a salt thereof. R may be alkenyl, aryl, aralkyl or alkaryl.  Preferred compounds are those wherein R is as above, R1 is hydrogen or 1 to 8 carbon alkyl and R11 is hydrogen e.g. N6 benzyladenine and N6-phenylethyladenine. Specified salts are those (a) with acids e.g. halogen acids; boric, sulphuric and phosphoric acids; aliphatic mono- and polycarboxylic acids which may be halogen or hydroxy substituted; alkane and aryl sulphonic acids; phosphonic acids, phosphinic acids and phosphorous acids; (b) with bases e.g. alkali metal and alkaline earth metal bases, ammonia, quaternary ammonium salts, sulphonium salts and phosphonium salts.  The antibiotic compositions may also be used in animal feeds as a growth promoter.  Specifications 854,560 and 953,897 are referred to.ALSO:A synergistic antibiotic composition comprises (a) an antibiotic being streptomycin, dihydro-streptomycin, chlortetracycline, chloramphenicol, oxytetracycline, tetracycline, neomycin, erythromycin, carbomycin or viomycin and (b) a synergistically effective amount of an N6-substituted adenine derivative having one of the following tautomeric formul <FORM:0978295/A5-A6/1> wherein R represents a hydrocarbyl group and the symbols R1 and R11 each individually represent a hydrogen atom or a hydrocarbyl group which may be substituted with one or more hydroxyl groups or the symbol R1 may represent a hydroxyl or amino group; or a salt thereof.  R may be alkenyl, aryl, aralkyl or alkaryl.  Preferred compounds are those where R is as above, R1 is hydrogen or 1 to 8 carbon alkyl and R11 is hydrogen, e.g. N6-benzyladenine and N6-phenylethyladenine.  Specified salts are those (a) with acids, e.g. halogen acids; boric, sulphuric and phosphoric acids; aliphatic mono- and poly-carboxylic acids which may be halogen or hydroxy substituted; alkane and aryl sulphonic acids; phosphonic acids, phosphinic acids and phosphorous acids; (b) with bases, e.g. alkali metal and alkaline earth metal bases, ammonia, quaternary ammonium salts, sulphonium salts and phosphonium salts. The compositions may be used medicinally, in the control of plant pathogens, in animal feeds as a growth promoter and as food preservatives.  Specifications 854,560 and 953,897 are referred to.
PURPOSE: Provided are a novel family of purified proteins designated as Bone Morphogenetic Protein-16 (BMP-16) and BMP-16-related proteins, DNA encoding them, and processes for obtaining them. These proteins may be used to induce bone and/or cartilage or other connective tissue formation, and in wound healing and tissue repair. These proteins may also be used for augmenting the activity of other bone morphogenetic proteins CONSTITUTION: Purified BMP-16 proteins and processes for producing them are disclosed. DNA molecules encoding the BMP-16 proteins are also disclosed. The proteins may be used in the treatment of bone, cartilage, other connective tissue defects and disorders, including tendon, ligament and meniscus, in wound healing and related tissue repair, as well as for treatment of disorders and defects to tissues which include epidermis, nerve, muscle, including cardiac muscle, and other tissues and wounds, and organs such as liver, lung, cardiac, pancreas and kidney tissue. The proteins may also be useful for the induction of growth and/or differentiation of undifferentiated embryonic and stem cells
PURPOSE:To obtain an emulsified composition for a cosmetic, by adjusting an oily phase component, an aqueous phase of a paraben or amino acid, and a clay mineral having a gelatinizing ability to a specific pH, mixing the components, and stirring the resultant mixture vigorously at a high temperature without using a surfactant. CONSTITUTION:An emulsified composition, consisting of 5-60wt% oily phase component, 40-90wt% aqueous phase component containing a paraben and/or amino acid and 0.5-5.0wt% clay mineral, e.g. synthetic hectorite, having the gelatinizing ability, each component being adjusting to a pH of 4.0-10.5 as base material components. The composition is prepared as follows: The respective components adjusted to the pH of 4.0-10.5 are mixed in a suitable order and stirred at about 70-90 deg.C, preferably about 80 deg.C, vigorously by a mixing stirrer. The resultant emulsion is then cooled or allowed to cool to give the aimed emulsified composition. EFFECT:The safe composition of uniform quality having almost no skin irritation is obtained without a change in physical properties with time. USE:A hand cream, foundation, food, coating material, shoe polish, etc.
Smoking cessation encompasses three guided smoking cessation group therapy sessions (6-12 participants per session) followed by smoking cessation (occuring in the second session) for 6 months. Participants receive an optional exercise programme and motivational coaching over the duration of the study.
The invention discloses an anti-uPAR humanized antibody, a coding gene and application thereof. The amino acid sequence of a heavy chain variable region of the antibody is shown as a sequence 3 in a sequence table, and the amino acid sequence of a light chain of the antibody is shown as a sequence 1 in the sequence table. Experiment results confirm that the antibody has good binding activity (affinity is 1.74*10-8 mol/L) and capability of inhibiting the growth and migration of tumor cells. The humanized antibody can be bound better to uPAR so as to guarantee anti-tumor effect thereof. A method for preparing the antibody can simultaneously express the light chain and a heavy chain and ensure that the expression ratio of the light chain to the heavy chain is closer to 1:1 so as to produce the antibody with double chains mutually matched in a higher ratio. In summary, the antibody and the preparation method thereof can have broad application prospects in the field of preventing and/or treating tumors.
Half of all subjects will receive active HD-tDCS (randomly assigned): anodal stimulation on the right dorsolateral prefrontal cortex. Stimulation will consist of 20 minutes 2mA anodal stimulation of the right dorsolateral prefrontal cortex.
The prevalence of the elderly with mild cognitive impairment accounts for one-fifth of the elderly population in Taiwan, and there is no medication that can effectively treat the disease. According to the literature review, there are many factors that cognitive impairment would influence. Many chronic diseases can induce cognitive decline, and depression is also related to cognitive function, including memory loss and cognitive decline. Mild cognitive impairment or dementia are also related to disability. Therefore, we choose the music, mood and movement(MMM) theory to connect psychology, cognitive function and physical fitness. The purpose of the research is to establish a model of the multimodal music therapy model and explore the effect of the multimodal music therapy on improving the mild cognitive impairment and mild dementia in the community. The senior with mild cognitive impairment and mild dementia are divided into an experimental group and a control group through randomization consisted of total 49 people based on different day care centers or community-based dementia care centers. It will take 12 weeks for the intervention. The experimental group received multimodal music intervention twice a week, each time with a duration of 70 minutes. The design method partly refers to the methods designed by Shimizu, including three musical instruments for the music therapy and physical activity, and the control group does not have any intervention. The experimental group and the control group have two weeks of pre-test and post-test, and the information sheet of demography, Montreal Cognitive Assessment, Saint Louis University Mental Status Exam, Trail Making Test, muscle strength and endurance, flexibility and dynamic balance ability, Geriatric Depression Scale would be collected before and after the 12-week intervention. The research data is analyzed with Statistical Product and Service Solutions(SPSS). We expect cognitive function, physical fitness and psychology can be improved through multimodal music therapy. This study is also the first time using music, mood and movement theory and applied to multimodal music therapy in Taiwan. If the research results are beneficial, this theory would become a beneficial choice for the elderly with cognitive decline.
Cachexia is a debilitating skeletal muscle wasting condition for which we currently lack effective treatments. In the context of cancer, certain chemotherapeutics cause DNA damage and cellular senescence. Senescent cells exhibit chronic activation of the transcription factor NF-κB, a known mediator of the proinflammatory senescence-associated secretory phenotype (SASP) and skeletal muscle atrophy. Thus, targeting NF-κB represents a logical therapeutic strategy to alleviate unintended consequences of genotoxic drugs. Herein, we show that treatment with the IKK/NF-κB inhibitor SR12343 during a course of chemotherapy reduces markers of cellular senescence and the SASP in liver, skeletal muscle, and circulation and, correspondingly, attenuates features of skeletal muscle pathology. Lastly, we demonstrate that SR12343 mitigates chemotherapy-induced reductions in body weight, lean mass, fat mass, and muscle strength. These findings support senescent cells as a promising druggable target to counteract the SASP and skeletal muscle wasting in the context of chemotherapy.
PURPOSE: To provide a tube which is radiation non-penetrative and optically transparent and has no possibility that even if the tube comes into contact with humor fluid and/or a liquid given to the body, poisonous matter leaks by using biological compatible polymer and radiation ray impermeable polymer halide. CONSTITUTION: A main body part 12 has an inner wall 16 and an outer wall 18. One or more stripes 20 of radiation ray impermeable polymer are arranged in the longitudinal direction along at least a part of the catheter length, and wrapped in the main body part 12. In the drawing, a catheter having preferable six stripes is shown, but it may have one to nine stripes. The catheter main body part may use any polymer if it is a thermoplastic base polymer which has biological compatibility and will not emit poisonous matter even if it comes into contact with a body fluid for a long time. Preferably, a polymer has flexibility and mechanical strength enough to be inserted in a winding body fluid passage.
Infants are fed bovine colostrum supplemented to mother's own milk (if avaible) for max. 10 days at RH and 14 days at FWCH \& SBMCH.
Arterial catheterization for continuous hemodynamic monitoring or frequent blood sampling is a common procedure in anesthesia and critical care setting. The most commonly used site for arterial catheterization is the radial artery because of its superficial course, alternate blood supply to hand via ulnar artery and a low rate of complications. Allen test is a simple, but not reliable, method for assessing the safety of radial artery catheterization. Intraarterial catheterization has some complications such as hematoma, vasospasm, arterial thrombosis, necrosis of skin overlying. Using larger size cannula from radial artery diameter, increase rate of complications. The purpose of this study is to investigate the corelation of radial artery diameter with sex, age, height, weight and body mass index for determination of proper cannula size and investigation of correlation between Allen test and doppler ultrasonography.
Cognitive Remediation (CR) is a form of group psychosocial intervention that uses a hybrid approach of restorative and strategy based methods to improve areas of cognition (ie. attention, memory, processing speed and learning) through the use of computerized exercises. Transcranial Direct Current Stimulation (tDCS): tDCS will be administered for 30 min/day, at the beginning of each group session. tDCS montage will be frontal with anode placed over Fz and the cathode over Iz. The direct current will be of 2 mA (current density = 0.57 A/m2). CR + tDCS is administered in groups consisting of 2-10 participants and one or two therapists. The groups meet 5 times per week for two hours per session over eight weeks, for a total of 40 sessions in induction phase. Afterwards 3 to 5 sessions per week on monthly boosters.
PROBLEM TO BE SOLVED: To obtain an oral preparation hardly causing discoloring even in long-term storage and excellent in quality by formulating S-(3-hydroxypropyl)- L-cysteine useful as an expectorant with a specific vehicle. SOLUTION: This oral preparation is obtained by formulating S-(3- hydroxypropyl)-L-cysteine (hereinafter referred to as HPCY) with a vehicle consisting substantially of only starch. Corn starch, potato starch or wheat starch can be exemplified as the starch and the starch is preferably used in an amount of 0.01-8 pts.wt. based on 1 pt.wt. HPCY. Cyclodextrins may be formulated with HPCY as the vehicle. α-Cyclodextrin, β-cyclodextrin, etc., can be exemplified as the cyclodextrins and the cyclodextrins are preferably used in an amount of 0.01-8 pts.wt. based on 1 pt.wt. HPCY.
ETHNOPHARMACOLOGICAL RELEVANCE: Non-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition that can have multiple underlying causes. There are no satisfactory chemical or biological drugs for the treatment of NAFLD. Longyasongmu, the bark and root of Aralia elata (Miq.) Seem, is used extensively in traditional Chinese medicine (TCM) and has been used in treating diverse liver diseases including NAFLD. Based on Aralia elata (Miq.) Seem as the main ingredient, Longya Gantai Capsules have been approved for use in China for the treatment of acute hepatitis and chronic hepatitis. Calenduloside E (CE), a natural pentacyclic triterpenoid saponin, is a significant component of saponin isolated from the bark and root of Aralia elata (Miq.) Seem. However, the role and mechanism of anti-NAFLD effects of CE is still unclear.
AIM OF THE STUDY: The objective of this study was to examine the potential mechanisms underlying the protective effect of CE on NAFLD.
MATERIALS AND METHODS: In this study, an NAFLD model was established by Western diet in apoE-/- mice, followed by treatment with various doses of CE (5 mg/kg, 10 mg/kg). The anti-NAFLD effect of CE was assessed by the liver injury, lipid accumulation, inflammation, and pro-fibrotic phenotype. The mechanism of CE in ameliorating NAFLD was studied through transcriptome sequencing (RNA-seq). In vitro, the mouse hepatocytes (AML-12) were stimulated in lipid mixtures with CE and performed the exploration and validation of the relevant pathways using Western blot, immunofluorescence, etc. RESULTS: The findings revealed a significant improvement in liver injury, lipid accumulation, inflammation, and pro-fibrotic phenotype upon CE administration. Furthermore, RNAseq analysis indicated that the primary pathway through which CE alleviates NAFLD involves pyroptosis-related inflammatory cascade pathways. Furthermore, it was observed that CE effectively suppressed inflammasome-mediated pyroptosis both in vivo and in vitro. Remarkably, the functional enrichment analysis of RNA-seq data revealed that the PI3K-Akt signaling pathway is the primarily Signaling transduction pathway modulated by CE treatment. Subsequent experimental outcomes provided further validation of CE's ability to hinder inflammasome-mediated pyroptosis through the inhibition of PI3K/AKT/NF-κB signaling pathway.
CONCLUSIONS: These findings present a novel pharmacological role of CE in exerting anti-NAFLD effects by inhibiting pyroptosis signaling pathways.
Oxybutynin chloride extended-release tablets are an antispasmodic, muscarinic antagonist. Each Oxybutynin chloride extended-release tablet contains 5 mg, 10 mg, or 15 mg of oxybutynin chloride USP, formulated as a once-a-day controlled-release tablet for oral administration. Oxybutynin chloride is administered as a racemate of R- and S-enantiomers.

Chemically, oxybutynin chloride is d,l (racemic) 4-diethylamino-2-butynyl phenylcyclohexylglycolate hydrochloride. The empirical formula of oxybutynin chloride is C22H31NO3•HCl.

Its structural formula is:

Oxybutynin chloride is a white crystalline solid with a molecular weight of 393.9. It is readily soluble in water and acids, but relatively insoluble in alkalis.

Oxybutynin chloride extended-release tablets also contain the following inert ingredients: black iron oxide, cellulose acetate, colloidal silicon dioxide, dextrose, hypromellose, lactose, magnesium stearate, mannitol, polyethylene glycol, propylene glycol, tartaric acid, titanium dioxide, triacetin.